Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Fondazione Telethon currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, resulting in a completely decentralized prosecution process where no two actions share the same reviewer. This diversity extends to the administrative level, with the portfolio being distributed across 4 distinct art units. This arrangement suggests a broad and varied technological focus within the company's patent filings.
The busiest examiner for this portfolio is MAHLUM, JONATHAN DAVIS, who is managing 1 pending office action. This single action is part of the 4 total pending office actions for the company. Because each of the 4 distinct examiners is assigned to exactly 1 pending action, the responsibility for the portfolio's progress is evenly split among them. The involvement of 4 distinct art units means that the applicant must navigate the specific requirements of four different divisions within the patent office. This complex landscape requires a highly individualized approach to each pending matter, as the preferences of 4 different examiners must be considered.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| GU, QINHUA | 1 | 75.9% | +27.8% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17285356 | INTEIN PROTEINS AND USES THEREOF | GU, QINHUA | — |
| 17284160 | SELECTION BY MEANS OF ARTIFICIAL TRANSACTIVATORS | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614268 | Agents and Methods for Treating Viral Infections | CUNNINGCHEN, KATHLEEN MARY | — |
| 17285356 | INTEIN PROTEINS AND USES THEREOF | GU, QINHUA | — |
| 17284160 | SELECTION BY MEANS OF ARTIFICIAL TRANSACTIVATORS | LIPPOLIS, ALEXANDRA ROSE | — |
| 16604484 | GENE THERAPY | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1633 | 1 |
| 1637 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17614268 | Agents and Methods for Treating Viral Infections | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103DPOther | Non-Final OA | — | Pending | Nov 24, 2021 |
| 17285356 | INTEIN PROTEINS AND USES THEREOF | GU, QINHUA | 1633 | §103§112 | Final Rejection | — | Pending | Apr 14, 2021 |
| 17284160 | SELECTION BY MEANS OF ARTIFICIAL TRANSACTIVATORS | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | — | Pending | Apr 09, 2021 |
| 16604484 | GENE THERAPY | JOHANSEN, PETER N. | 1644 | §103 | Non-Final OA | — | Pending | Oct 10, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial